# US 2012/0251540 A1 · Stabilized single domain antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251540 A1
- Document ID: US20120251540A1
- Status: Published application
- Kind: A1
- Application number: 13/422,024
- Filed: 2012-03-16
- Published: 2012-10-04
- Earliest claimed: 2002-11-08
- Assignees: Ablynx N.V.
- Inventors: Karen Silence; Marc Jozef Lauwereys; Torsten Dreier
- Web page: https://patentgrep.com/patent/US20120251540A1

## CPC

- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/06: Antianaemics
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 21/04: for myasthenia gravis
- A61P 25/02: for peripheral neuropathies
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/06: for tuberculosis
- A61P 31/16: for influenza or rhinoviruses
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/18: against material from animals or humans
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 16/249: {Interferons}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- C07K 16/36: against blood coagulation factors
- C07K 16/40: against enzymes
- C07K 16/42: against immunoglobulins
- C07K 16/4291: {against IgE}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/626: Diabody or triabody
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/00: Fusion polypeptide
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems.

## Claims

### Claim 1

A polypeptide construct comprising a first immunoglobulin single variable domain having a first antigen or epitope binding specificity and a second immunoglobulin single variable domain having a second antigen or epitope binding specificity wherein one or both of said first and second variable domains bind to an antigen or epitope which increases the half-life of the ligand in vivo, and either (i) the first and the second immunoglobulin variable domains are heavy chain variable domains; or (ii) the first and the second immunoglobulin variable domains are light chain variable domains.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The polypeptide construct of claim 1, wherein the heavy chain domains are Camelid VHH domains.

### Claim 5 (depends on 1)

The polypeptide construct according to claim 1, wherein the first, and second domains bind independently, such that the polypeptide may simultaneously bind both the first and second epitopes or antigens.

### Claim 6 (depends on 1)

The polypeptide construct according to claim 1, wherein said first and second epitopes are present on separate antigens.

### Claim 7 (depends on 1)

The polypeptide construct according to claim 1, wherein said first and second epitopes are present on the same antigen.

### Claim 8 (depends on 1)

The polypeptide construct according to claim 1 wherein the variable regions are covalently associated.

### Claim 9 (depends on 1)

The polypeptide construct according to claim 1 wherein the first and the second immunoglobulin variable domains are heavy chain variable domains.

### Claim 10 (depends on 1)

The polypeptide construct according to claim 1, comprising a single variable domain specific for serum albumin (SA) which has a dissociation constant (Kd) of 1 nM to 500 μM for SA, as determined by surface plasmon resonance.

### Claim 11

(canceled)

### Claim 12 (depends on 10)

The polypeptide construct according to claim 10, wherein the SA is in human form.

### Claim 13

A polypeptide construct comprising an anti-human TNF alpha single domain antibody (dAb) and an anti-serum albumin (SA) dAb,
wherein each of the anti-human TNF alpha dAb and the anti-SA dAb is a heavy chain variable domain; or
wherein each of the anti-human TNF alpha dAb and the anti-SA dAb is a light chain variable domain.

### Claim 14

A polypeptide construct comprising an anti-human TNF alpha Camelid VHH domain and an anti-serum albumin (SA) Camelid VHH domain.

### Claim 15 (depends on 13)

The polypeptide construct according to claim 13, wherein the anti-SA dAb has a dissociation constant (Kd) of 1 nM to 500 μM for SA, as determined by surface plasmon resonance.

### Claim 16 (depends on 1)

The polypeptide construct according to a claim 1, wherein the heavy chain variable domain is not a Camelid immunoglobulin variable domain.

### Claim 17 (depends on 16)

The polypeptide construct of claim 16, wherein the heavy chain variable domain does not contain one or more amino acids that are specific to Camelid immunoglobulin variable domains as compared to human VH domains.

### Claim 18 (depends on 1)

The polypeptide construct according to claim 1, which comprises a universal framework.

### Claim 19 (depends on 1)

The polypeptide construct according to claim 1 comprising a VH framework selected from the group consisting of DP47, DP45 and DP38; and/or a VL framework which is DPK9.

### Claim 20 (depends on 1)

The polypeptide construct according to claim 1 wherein the ligand comprises a variable domain having one or more framework regions comprising an amino acid sequence that is the same as the amino acid sequence of a corresponding framework region encoded by a human germline antibody gene segment, or the amino acid sequences of one or more of said framework regions collectively comprises up to 5 amino acid differences relative to the amino acid sequence of said corresponding framework region encoded by a human germline antibody gene segment.

### Claim 21 (depends on 1)

The polypeptide construct according to claim 1, wherein the ligand comprises a variable domain, wherein the amino acid sequences of FW1, FW2, FW3 and FW4 are the same as the amino acid sequences of corresponding framework regions encoded by a human germline antibody gene segment, or the amino acid sequences of FW1, FW2, FW3 and FW4 collectively contain up to 10 amino acid differences relative to the amino acid sequences of corresponding framework regions encoded by said human germline antibody gene segment.

### Claim 22 (depends on 21)

The polypeptide construct according to claim 21, which comprises an antibody variable domain comprising FW1, FW2 and FW3 regions, and the amino acid sequences of said FW1, FW2 and FW3 are the same as the amino acid sequences of corresponding framework regions encoded by human germline antibody gene segments.

### Claim 23 (depends on 20)

The polypeptide construct according to claim 20, wherein said human germline antibody gene segment is selected from the group consisting of DP47, DP45, DP48 and DPK9.

### Claim at position 24

-29. (canceled)

### Claim 30 (depends on 1)

A pharmaceutical composition comprising the polypeptide construct according to claim 1, and a pharmaceutically acceptable excipient, carrier or diluent.

### Claim 31

A polypeptide construct comprising a first immunoglobulin single variable domain having binding specificity for serum albumin (SA), and a second immunoglobulin single variable domain having binding specificity for an antigen selected from the group consisting of IFN-γ, tumour necrosis factor (TNF), TNF-α, and IFN-gamma-receptor,
wherein each of the first and second single variable domains is a heavy chain variable domain; or
wherein each of the first and second single variable domains is a light chain variable domain.

### Claim 32

A polypeptide construct comprising a first immunoglobulin single variable domain having binding specificity for serum albumin (SA), and a second immunoglobulin single variable domain having binding specificity for an antigen selected from the group consisting of human or animal proteins, cytokines, cytokine receptors, and enzymes,
wherein each of the first and second single variable domains is a heavy chain variable domain; or
wherein each of the first and second single variable domains is a light chain variable domain.

### Claim 33 (depends on 31)

A polypeptide construct comprising a first immunoglobulin single variable domain having binding specificity for serum albumin (SA), and a second single immunoglobulin variable domain having binding specificity for a receptor for a cytokine listed in claim 31,
wherein each of the first and second single variable domains is a heavy chain variable domain; or
wherein each of the first and second single variable domains is a light chain variable domain.

### Claim 34

(canceled)

### Claim 35 (depends on 31, 32)

The polypeptide construct of claim 31, 32, or 33, wherein the anti-SA domain has a dissociation constant (Kd) of 1 nM to 500 μM for SA, as determined by surface plasmon resonance.

### Claim 36

A variable domain specific for serum albumin (SA) which has a dissociation constant (Kd) of 1 nM to 500 μM for SA, as determined by surface plasmon resonance.

### Claim 37 (depends on 36)

The variable domain according to claim 36, wherein the SA is in human form.

### Claim at position 33

-40. (canceled)

### Claim 41 (depends on 36)

A pharmaceutical composition comprising the variable domain according to claim 36, and a pharmaceutically acceptable recipient, carrier or diluent.

### Claim 42 (depends on 36)

A polypeptide construct comprising (i) first and second heavy chain single variable domains, or (ii) first and second light chain single variable domains, wherein the first variable domain is a variable domain as defined in claim 36.

### Claim 43 (depends on 42)

The polypeptide construct of claim 42, which is a dimer.

### Claim 44

A polypeptide construct comprising a dimer, trimer or tetrameter of (i) heavy chain single variable domains or (ii) light chain single variable domains, the domains being specific for the same epitope or adjacent epitopes on the same target.

### Claim 45

A polypeptide construct comprising (i) first and second heavy chain single variable domains or (ii) first and second light chain single variable domains, the domains having the same epitope specificity, wherein the epitope is provided as multiple copies by TNF alpha.

### Claim 46

A polypeptide construct comprising (i) first and second heavy chain single variable domains, or (ii) first and second light chain single variable domains, wherein each domain has binding specificity to an epitope or antigen with a dissociation constant (Kd) of 1×10−7 M or less, as determined by surface plasmon resonance.

### Claim 47 (depends on 46)

The polypeptide construct of claim 46, wherein each domain has binding specificity to an epitope or antigen with a dissociation constant (Kd) of 50 nM to 20 pM, as determined by surface plasmon resonance.

### Claim 48 (depends on 46)

The polypeptide construct of claim 46, wherein the first and second domains are identical.

### Claim 49

A polypeptide construct comprising (i) first and second heavy chain single variable domains, or (ii) first and second light chain single variable domains, wherein each domain has binding specificity to an antigen selected from the group consisting of human or animal proteins, cytokines, and cytokine receptors.

### Claim 50 (depends on 49)

The polypeptide construct according to claim 49, wherein the cytokine receptor is IFN gamma receptor.

### Claim 51

A polypeptide construct comprising (i) first and second heavy chain single variable domains, or (ii) first and second light chain single variable domains, wherein each domain has binding specificity to an antigen selected from the group consisting of IFN-gamma, tumour necrosis factor (TNF), TNF-alpha, and IFN gamma receptor.

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54 (depends on 31, 44, 45, 46, 49, 51)

The polypeptide construct of claim 31, 44, 45, 46, 49 or 51, wherein the or each variable domain is a Camelid VHH domain.
